| Literature DB >> 30283000 |
Ina Dervishi1, Oge Gozutok1, Kevin Murnan1, Mukesh Gautam1, Daniel Heller1, Eileen Bigio2,3, P Hande Ozdinler4,5,6,7.
Abstract
Developing effective treatment strategies for neurodegenerative diseases require an understanding of the underlying cellular pathways that lead to neuronal vulnerability and progressive degeneration. To date, numerous mutations in 147 distinct genes are identified to be "associated" with, "modifier" or "causative" of amyotrophic lateral sclerosis (ALS). Protein products of these genes and their interactions helped determine the protein landscape of ALS, and revealed upstream modulators, key canonical pathways, interactome domains and novel therapeutic targets. Our analysis originates from known human mutations and circles back to human, revealing increased PPARG and PPARGC1A expression in the Betz cells of sALS patients and patients with TDP43 pathology, and emphasizes the importance of lipid homeostasis. Downregulation of YWHAZ, a 14-3-3 protein, and cytoplasmic accumulation of ZFYVE27 especially in diseased Betz cells of ALS patients reinforce the idea that perturbed protein communications, interactome defects, and altered converging pathways will reveal novel therapeutic targets in ALS.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30283000 PMCID: PMC6170493 DOI: 10.1038/s41598-018-32902-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
List of genes that are reported to be “Causative”, “Associated” and “Disease Modifier” with respect to ALS disease.
|
|
| ALS2, ALS3, ALS7, ANG, ANXA11, ATXN2, CFAP410, C9orf72, CHCHD10, CHMP2B, DAO, DCTN1, ELP3, ERBB4, Erlin1, FIG4, FUS, HNRNPA1, LMNB1, MATR3, NEFH, NEK1, OPTN, PFN1, PRPH, SETX, SIGMAR1, SOD1, SPAST, SPG11, SQSTM1, TAF15, TARDBP, TIA1, TUBA4A, UBQLN2, UNC13A, VAPB, VCP. |
|
|
| AGT, ALAD, APEX1, APOE, AR, ARHGEF28, ATRN, ATXN1, B4GALT6, BCL6, BCL11B, BIRC6, C1orf27, C1QTNF7, CCNF, CCS, CDH13, CDH22, CHGB, CNTF, CNTN4, CNTN6, CREB3L2, CRIM1, CRYM, CSNK1G3, CST3, CX3CR1, CYP2D6, DCC, DIAPH3, DISC1, DOC2B, DPP6, DYNC1H1, EFEMP1, EPHA4, EWSR1, FEZF2, FGGY, GARS, GLE1, GRB14, GRN, HEXA, HFE, HNRNPA2B1, ITPR2, KCNN1, KDR, KIF5A, KIFAP3, LIF, LIPC, LOX, LUM, MAOB, MAPT, MOBP, MT-ND2, NAIP, NETO1, NIPA1, NT5C1A, OGG1, OMA1, PARK7, PCP4, PEAK1, PLEKHG5, POLDIP2, PON1, PON2, PON3, PSEN1, PVR, RAMP3, RBMS1, RNASE2, RNF19A, SARM1, SCFD1, SCN7A, SELL, SEMA6A, SLC1A2, SLC39A11, SMN1, SMN2, SNCG, SOD2, SOX5, SPG7, SS18L1, STX12, SUSD1, SYNE, SYT9, TBK1, TRPM7, VDR, VEGFA, VPS54, WDR49, ZFP64, ZNF746, ZNF512B, ZSCAN5B. |
*Please see Supplementary Table 1 for references.
List of post-mortem human cases included in this study. The table shows Clinical-Pathological diagnosis, age, sex, PMI/h, and the type of TDP43 inclusions observed in patients. NCIs: neuronal cytoplasmic inclusions; GIs: glial/microglial cytoplasmic inclusions; DNs: extracellular dystrophic neurites; PMI/h: post-mortem interval in hrs.
| Clinical-Pathological Diagnosis | Case # | Age | Sex | PMI/h | Type of TDP-43 inclusion | ||
|---|---|---|---|---|---|---|---|
| TDP + NCIs | TDP + GIs | TDP + DNs | |||||
| ALS with TDP43 | 1 | 61 | M | 29 | + | 0 | 0 |
| ALS with TDP43 | 2 | 64 | M | 24 | + | ++ | + |
| ALS with TDP43 | 3 | 61 | M | 13 | + | 0 | 0 |
| ALS with TDP43 | 4 | 64 | M | 14 | 0 | + | 0 |
| ALS with TDP43 | 5 | 64 | F | 19 | + | + | 0 |
| ALS with TDP43 | 6 | 73 | M | 23 | 0 | + | 0 |
| ALS with TDP43 | 7 | 57 | M | 18 | + | +++ | 0 |
| ALS with TDP43 | 8 | 40 | M | 19 | + | ++ | + |
| ALS with TDP43 | 9 | 82 | F | 36 | ++ | 0 | 0 |
| Sporadic ALS | 10 | 66 | F | 12 | |||
| Sporadic ALS | 11 | 71 | F | 15 | |||
| Sporadic ALS | 12 | 64 | F | 9 | |||
| Sporadic ALS | 13 | 55 | M | 16 | |||
| Sporadic ALS | 14 | 53 | M | 6 | |||
| Sporadic ALS | 15 | 51 | M | 19 | |||
| Sporadic ALS | 16 | 63 | M | 21 | |||
| Sporadic ALS | 17 | 61 | M | 17 | |||
| Normal Control | 18 | 66 | F | 18 | |||
| Normal Control | 19 | 62 | F | 15 | |||
| Normal Control | 20 | 54 | M | 12 | |||
| Normal Control | 21 | 64 | M | 10 | |||
| Normal Control | 22 | 63 | M | 8 | |||
| Normal Control | 23 | 59 | M | 12 | |||
| Normal Control | 24 | 69 | M | 12 | |||
| Normal Control | 25 | 60 | M | 19 | |||
| Normal Control | 26 | 72 | M | 14 | |||
| Normal Control | 27 | 45 | F | 15 | |||
| Normal Control | 28 | 67 | M | 5 | |||
| Normal Control | 29 | 74 | M | 8 | |||
Figure 1Distribution of ALS proteins based on location and type. (a) Bar graph representing the top binding partners ranked based on the number of interactions they have with protein products of genes linked and associated with ALS. (b,c) Pie charts show the distribution of ALS proteins based on their cellular location (b) and protein type (c,d) the circular plot shows the relationship between location and type of ALS proteins.
Figure 2Upstream regulators for ALS proteins. (a) Table of upstream regulators, the number of their binding partners, their predicted activation state and score, and p-value of overlap. (b) Representative image of PPARG expression in the Betz cells of control cases (n = 12). PPARG is detected in the cytoplasm and in some cases in the nucleus. (c) Representative images of PPARG expression in the Betz cells of sporadic ALS patients (n = 8). (d) Representative images of PPARG expression in the Betz cells of ALS patients with TDP43 pathology (n = 9). (e) Representative image of PPARGC1A expression in the Betz cells of control cases (n = 12). PPARG is low but is detected in the cytoplasm. (f) Representative images of PPARGC1A expression in the Betz cells of sporadic ALS patients (n = 8). (g) Representative images of PPARGC1A expression in the Betz cells of sporadic ALS patients (n = 8). PPARGC1A expression is increased and the proteins is accumulated in the cytoplasm, z-score ≥2 and p ≥ 0.05 is significant. Scale bar = 50 μm in b-g.
Figure 3Involvement of ALS proteins in lipid homeostasis. (a) Bar graphs of canonical pathways involved in lipid homeostasis, as highlighted by ALS protein interactions (−p(log value)) and their overlap (ratio, yellow line). (b) Image of PPAR Signaling pathway, representing the extent of ALS protein involvement. ALS proteins with higher binding partners are marked with increasing color intensity. (c) Circular representation of ALS proteins that are commonly present among different canonical pathways.
Figure 4Involvement of ALS proteins in protein homeostasis. (a) Bar graphs of canonical pathways involved in protein homeostasis, as highlighted by ALS protein interactions (−p(log value)) and their overlap (ratio, yellow line). (b) Image of Unfolded protein response pathway, representing the extent of ALS protein involvement. ALS proteins with higher binding partners are marked with increasing color intensity. (c) Circular representation of ALS proteins that are commonly present among different canonical pathways.
Figure 5Involvement of ALS proteins in response to hypoxic insult. (a) Bar graphs of canonical pathways involved in response to hypoxic insult, as highlighted by ALS protein interactions (−p(log value)) and their overlap (ratio, yellow line). (b) Image of NRF-2 mediated oxidative stress response pathway, representing the extent of ALS protein involvement. ALS proteins with higher binding partners are marked with increasing color intensity. (c) Circular representation of ALS proteins that are commonly present among different canonical pathways.
Figure 6Involvement of ALS proteins in DNA damage and repair. (a) Bar graphs of canonical pathways involved in DNA damage and repair, as highlighted by ALS protein interactions (−p(log value)) and their overlap (ratio, yellow line). (b) Image of ATM signaling pathway, representing the extent of ALS protein involvement. ALS proteins with higher binding partners are marked with increasing color intensity. (c) Circular representation of ALS proteins that are commonly present among different canonical pathways.
Figure 7Involvement of ALS proteins in cytoskeleton dynamics. (a) Bar graphs of canonical pathways involved in cytoskeleton dynamics, as highlighted by ALS protein interactions (−p(log value)) and their overlap (ratio, yellow line). (b) Image of Actin cytoskeleton pathway, representing the extent of ALS protein involvement. ALS proteins with higher binding partners are marked with increasing color intensity. (c) Circular representation of ALS proteins that are commonly present among different canonical pathways.
Figure 8Involvement of ALS proteins in growth factor mediated signaling pathways. (a) Bar graphs of growth factor mediated signaling pathways, as highlighted by ALS protein interactions (−p(log value)) and their overlap (ratio, yellow line). (b,c) Image of CNTF signaling pathway(a) and IGF-1 signaling representing the extent of ALS protein involvement. ALS proteins with higher binding partners are marked with increasing color intensity. (d,e,f) Circular representation of ALS proteins that are commonly present among different canonical pathways per cellular location: plasma membrane (d), nuclear (e), cytoplasm (f).
Figure 9YWHAZ expression is reduced in the Betz cells of ALS patients. (a) Representative image of the motor cortex in control cases (n = 12). Betz cells are located in layer V and can be visualized based on their high-level and selective YWHAZ expression. (b) Representative images of control Betz cells, expressing high levels of YWHAZ in their cytoplasm, and apical dendrites. (c) Low magnification view of the motor cortex in sporadic ALS cases (n = 8), displaying reduced levels of YWHAZ expression in Betz cells. (d) Representative images of sporadic ALS patient Betz cells, and (e) Betz cells of ALS patients with TDP43 pathology (n = 9), expressing reduced levels of YWHAZ, where the protein is mainly localized along the cell membrane. Scale bar = 150 μm (a,c); scale bar = 50 μm (b,d).
Figure 10Protein interactome analysis suggests the importance of ZFYVE27. (a) ZFYVE27 is at the center of a prominent protein interactome domain. (b) ZFYVE27 is the upstream regulator of proteins present in the interactome domain. (c) Representative images of Betz cells in control cases (n = 12). ZFYVE27 is present in the cytoplasm at low levels. (d) Representative images of Betz cells in sporadic ALS patients (n = 8). (e) Representative images of Betz cells in ALS patients with TDP43 pathology (n = 9). ZFYVE27 expression is increased and protein is accumulated in discrete regions within the cytoplasm. Scale bar = 50 μm in c–e.